{{Drugbox
| verifiedrevid = 476996826
| IUPAC_name = (3-amino-1-hydroxypropane-1,1-diyl)bis(phosphonic acid)
| image = Pamidronic acid.svg
<!--Clinical data-->
| tradename =  
| Drugs.com = {{drugs.com|international|pamidronic-acid}}
| MedlinePlus = a601163
| pregnancy_AU = B3
| pregnancy_US = D
| legal_AU = <!-- Unscheduled / S2 / S4 / S8 -->
| legal_UK = POM
| legal_US = Rx-only
| routes_of_administration = [[Intravenous therapy|Intravenous]]
<!--Pharmacokinetic data-->
| bioavailability = n/a
| protein_bound = 54%
| metabolism = Nil
| elimination_half-life = 28 ± 7 hours
| excretion = [[Kidney|Renal]]
<!--Identifiers-->
| IUPHAR_ligand = 7259
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 40391-99-9
| ATC_prefix = M05
| ATC_suffix = BA03
| PubChem = 4674
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB00282
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 4512
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = OYY3447OMC
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D07281
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 834
<!--Chemical data-->
| C=3 | H=11 | N=1 | O=7 | P=2
| molecular_weight = 235.07 g/mol
| smiles = O=P(O)(O)C(O)(CCN)P(=O)(O)O
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C3H11NO7P2/c4-2-1-3(5,12(6,7)8)13(9,10)11/h5H,1-2,4H2,(H2,6,7,8)(H2,9,10,11)
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = WRUUGTRCQOWXEG-UHFFFAOYSA-N
}}
'''Pamidronic acid''' ([[International Nonproprietary Name|INN]]) or '''pamidronate disodium''' ([[United States Approved Name|USAN]]), '''pamidronate disodium pentahydrate''' is a [[nitrogen]]-containing [[bisphosphonate]], used to prevent [[osteoporosis]]. It is marketed by [[Novartis]] under the brand name '''Aredia'''. In India, it is marketed by Curacell Biotech under the brand name '''Pamimed'''.

==Uses==
It is used to prevent [[bone]] loss, and treat [[osteoporosis]].  It is also used to strengthen bone in [[Paget's disease of bone|Paget's disease]], to prevent bone loss due to [[glucocorticoid|steroid]] use, and in certain [[cancer]]s with high propensity to bone, such as [[multiple  myeloma]]. Due to its ability to sequester [[calcium]] in bone, it is also used to treat [[hypercalcemia|high calcium levels]].
It is also used as an experimental treatment of the bone disorder known as [[Osteogenesis Imperfecta]].  It has been studied in the treatment of [[Complex Regional Pain Syndrome]].<ref name = Kubalek>{{cite journal | author= I. Kubalek | author2= O. Fain | author3= J. Paries | author4= A. Kettaneh | author5 = M. Thomas | title = Treatment of reflex sympathetic dystrophy with pamidronate: 29 cases. | journal = 
Rheumatology | volume = 40 | issue =  12 | pages = 1394–1397 | year = 2001 | pmid = 11752511 |  doi = 10.1093/rheumatology/40.12.1394 }}</ref>

==Administration==
[[Intravenous]], usually 90&nbsp;mg monthly.  30&nbsp;mg, 60&nbsp;mg, 90&nbsp;mg and for hospitals, 120&nbsp;mg vials are available, mixed with [[mannitol]].

==Side effects==
Common side effects include bone pain, [[hypocalcemia|low calcium levels]], [[nausea]], and [[dizziness]].
[[Osteonecrosis of the jaw]] is a rare complication which has been associated with the use of bisphosphonates, including pamidronate.<ref name = Zarychanski>{{cite journal |vauthors=Zarychanski R, Elphee E, Walton P, Johnston J | title = Osteonecrosis of the jaw associated with pamidronate therapy. | journal = Am J Hematol | volume = 81 | issue = 1 | pages = 73–5 | year = 2006 | pmid = 16369966 | doi = 10.1002/ajh.20481}}</ref>

Pamidronate activates human [[gamma/delta T cells|γδ T cells]] ''[[in vitro]]'' and ''[[in vivo]]'', which may lead to [[flu-like symptoms]] upon administration.

==References==
{{reflist}}

{{Bisphosphonates}}

[[Category:Bisphosphonates]]
[[Category:Farnesyl pyrophosphate synthase inhibitors]]


{{musculoskeletal-drug-stub}}